Biocardia, Inc. (BCDA) — SEC Filings
Biocardia, Inc. (BCDA) — 50 SEC filings. Latest: 8-K (May 8, 2026). Includes 39 8-K, 3 10-Q, 2 10-K.
View Biocardia, Inc. on SEC EDGAR
Overview
Biocardia, Inc. (BCDA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 28, 2026: BioCardia, Inc. filed an 8-K on April 28, 2026, reporting other events and financial statements/exhibits. The filing details include the company's mailing and business address in Sunnyvale, CA, and its CIK number 0000925741. The report is categorized under Item 8.01 (Other Events) and Item 9.01 (Fin
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 6 bearish, 42 neutral, 2 mixed. The dominant filing sentiment for Biocardia, Inc. is neutral.
Filing Type Overview
Biocardia, Inc. (BCDA) has filed 39 8-K, 1 S-8, 2 10-K, 3 10-Q, 1 DEF 14A, 1 10-Q/A, 1 S-1/A, 1 S-1, 1 SC 13G with the SEC between Sep 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of BCDA's 42 recent filings, 7 were flagged as high-risk, 7 as medium-risk, and 28 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0.00 |
| Net Income | -$36.3 million |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $10.6 million |
| Operating Margin | N/A |
| Total Assets | $21.9 million |
| Total Debt | $0.00 |
Key Executives
- Peter Altman, Ph.D.
- Andrew Blank
- Marvin Slosman
- Jay M. Moyes
- Simon H. Stertzer, M.D.
- David McClung
- Peter Altman
- Michael J. Danaher
- Austin D. March
Industry Context
BioCardia operates in the highly competitive and rapidly evolving fields of cardiovascular and pulmonary disease therapeutics. The market is characterized by significant unmet needs, particularly in heart failure, driving substantial investment in novel cell and gene therapies. Key trends include the development of regenerative medicine approaches and advanced drug delivery systems, with companies like BioCardia aiming to leverage these innovations to address limitations of current treatments.
Top Tags
filing (14) · 8-k (10) · financials (10) · sec-filing (9) · 8-K (8) · corporate-update (7) · regulatory (5) · Biotechnology (5) · Clinical Stage (4) · Dilution Risk (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CIK Number | 0000925741 | Identifier for BioCardia, Inc. |
| Filing Date | 2026-04-28 | Date the 8-K was accepted and filed. |
| aggregate market value of non-affiliate common equity | $9.7 million | as of June 30, 2025, indicating a small market capitalization |
| shares of Common Stock issued and outstanding | 10,940,372 | as of March 24, 2026 |
| relative risk reduction in heart death equivalents | 47% | in patients with elevated NTproBNP biomarkers in CardiAMP HF trial |
| improvement in quality-of-life score (MLHFQ) | 10.5-point | in patients with elevated NTproBNP biomarkers in CardiAMP HF trial |
| relative risk reduction in non-fatal MACCE | 44.6% | in all treated patients in CardiAMP HF trial |
| American adults with heart failure | 6.7 million | estimated by AHA in 2024 |
| projected total cost of heart failure | $69.8 billion | by 2030, up from $30.7 billion in 2012 |
| date of FDA Breakthrough Device Designation | January 2022 | for CardiAMP Cell Therapy System |
| advanced heart failure patients enrolled | 115 | in the randomized CardiAMP HF trial |
| Fiscal Year End | 1231 | Indicates the end of the company's fiscal year |
| Net Loss (Q3 2025) | $1.48M | Improved from $1.74M in Q3 2024 |
| Net Loss (9M 2025) | $6.24M | Increased from $5.65M in 9M 2024 |
| Cash & Cash Equivalents | $5.29M | As of September 30, 2025, up from $2.37M at Dec 31, 2024 |
Frequently Asked Questions
What are the latest SEC filings for Biocardia, Inc. (BCDA)?
Biocardia, Inc. has 50 recent SEC filings from Sep 2024 to May 2026, including 39 8-K, 3 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BCDA filings?
Across 50 filings, the sentiment breakdown is: 6 bearish, 42 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Biocardia, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biocardia, Inc. (BCDA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biocardia, Inc.?
Key financial highlights from Biocardia, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BCDA?
The investment thesis for BCDA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biocardia, Inc.?
Key executives identified across Biocardia, Inc.'s filings include Peter Altman, Ph.D., Andrew Blank, Marvin Slosman, Jay M. Moyes, Simon H. Stertzer, M.D. and 4 others.
What are the main risk factors for Biocardia, Inc. stock?
Of BCDA's 42 assessed filings, 7 were flagged high-risk, 7 medium-risk, and 28 low-risk.
What are recent predictions and forward guidance from Biocardia, Inc.?
Forward guidance and predictions for Biocardia, Inc. are extracted from SEC filings as they are enriched.